Siemens Healthineers confirms outlook despite problems at Varian
Reuters
Published Aug 02, 2023 01:06AM ET
Updated Aug 02, 2023 04:19AM ET
(Reuters) -U.S.-German medical device maker Siemens Healthineers (ETR:SHLG) on Wednesday confirmed its outlook for the year despite an unexpected drop in quarterly operating profit amid delivery delays at cancer treatment specialist Varian.
Adjusted earnings before interest and taxes (EBIT) fell 3% to 740 million euros ($812.59 million) in the third quarter, below the 773 million euros expected by analysts according to a consensus provided by the company.
Shares were down 5.3% in Frankfurt early trade after the results.
Revenue in the quarter gained 3.6% on a comparable basis, helped by growth in the Imaging and Advanced Therapies segments, to 5.1 billion euros, in line with analysts' expectations. Net income was nearly a quarter higher than the prior-year period thanks to a low tax rate.
Excluding the COVID-19 rapid antigen test business, comparable revenue growth was 10.1% for the April-June quarter.
Chief Executive Bernd Montag spoke of a "a quarter of strong growth" and told journalists that the company would hit the upper end of its full-year forecast of comparable revenue change of between -1% and 1%.
However, Siemens Healthineers lowered its profit margin outlook for Varian due to "temporary challenges in outbound logistics" at its U.S. maker of devices and software for treating cancer to 14-15% from a previous 16-18%.
Delivery problems will be solved in the fourth quarter, said Chief Financial Officer Jochen Schmitz, adding that order intake at Varian has been consistently high.
For the quarter, Varian's profit dropped by nearly a third, to 102 million euros, with the margin also falling by 6 percentage points to 12.1% from the same period last year.
Jefferies said a weak order intake and Varian figures overshadowed "a strong performance in Imaging and a decent Diagnostics print."
Falling test demand hit the Diagnostics segment, whose revenue fell 20.1% on a comparable basis, but rose by 2.0% when excluding tests, while the Imaging segment posted broad-based comparable revenue growth of 15.2% for the quarter.
($1 = 0.9084 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.